greeksoup/ stock research
Stock research / United States / ABBV · Pharmaceutical Preparations · NYSE

AbbVie Inc. (ABBV)

AbbVie is a research-based biopharmaceutical company with products across immunology, neuroscience, oncology and aesthetics, plus eye care and several other areas. It was incorporated in Delaware on 10 April 2012 and became an independent, publicly traded company on 1 January 2013, when Abbott Laboratories distributed all of AbbVie's outstanding common stock to Abbott's shareholders. It operates as a single global business segment: one global research and development and supply chain organisation discovers, develops, manufactures and supplies the products, while the commercial effort that markets, sells and distributes them is organised by geographic region or therapeutic area.

AbbVie Inc.

AbbVie is a research-based biopharmaceutical company with products across immunology, neuroscience, oncology and aesthetics, plus eye care and several other areas. It was incorporated in Delaware on 10 April 2012 and became an independent, publicly traded company on 1 January 2013, when Abbott Laboratories distributed all of AbbVie's outstanding common stock to Abbott's shareholders. It operates as a single global business segment: one global research and development and supply chain organisation discovers, develops, manufactures and supplies the products, while the commercial effort that markets, sells and distributes them is organised by geographic region or therapeutic area.

Immunology

The portfolio spans rheumatology, dermatology and gastroenterology, and rests on two medicines. Skyrizi, risankizumab, is an interleukin-23 inhibitor that blocks IL-23 by binding to its p19 subunit, approved across autoimmune diseases in North America, the European Union and Japan. Rinvoq, upadacitinib, is an oral, once-daily selective and reversible JAK inhibitor approved in the same three regions and sold in numerous other markets. In the United States, Rinvoq covers rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease in adults who have not responded to or cannot tolerate tumor necrosis factor blockers, psoriatic arthritis in patients two years and older, and atopic dermatitis in adults and adolescents.

Neuroscience

Vraylar, cariprazine, is a dopamine receptor partial agonist for schizophrenia, manic or mixed episodes of bipolar disorder, bipolar I depression and as an add-on in major depressive disorder. Botox Therapeutic, onabotulinumtoxinA, is an injectable acetylcholine release inhibitor and neuromuscular blocking agent approved in the United States for chronic migraine, overactive bladder, spasticity in patients two years and older and cervical dystonia, among other conditions; it is marketed by GSK in Japan. Ubrelvy treats a migraine attack and Qulipta, sold as Aquipta in the European Union, prevents episodic and chronic migraine, both being calcitonin gene-related peptide receptor antagonists. For advanced Parkinson's disease there is Vyalev, a subcutaneous 24-hour infusion of levodopa-based therapy, sold mainly as Produodopa outside the United States, and Duodopa, an intestinal gel, sold as Duopa in the United States.

Oncology

Imbruvica, ibrutinib, is an oral once-daily Bruton's tyrosine kinase inhibitor for blood cancers including chronic lymphocytic leukemia and certain non-Hodgkin lymphomas, and for chronic graft versus host disease. Venclexta, venetoclax, is a BCL-2 inhibitor for chronic lymphocytic leukemia and, in combination, newly diagnosed acute myeloid leukemia in older patients; it is Venclyxto outside the United States. Elahere is an antibody-drug conjugate for FRα positive, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Epkinly, sold as Tepkinly outside the United States, is a subcutaneous injection for certain diffuse large B-cell and high-grade B-cell lymphomas and for relapsed or refractory follicular lymphoma. Emrelis is an antibody-drug conjugate for non-squamous non-small cell lung cancer with high c-Met protein overexpression.

Aesthetics, eye care and the rest

Aesthetics is facial injectables, plastics and regenerative medicine, body contouring and skincare. Botox Cosmetic treats frown lines, crow's feet, forehead lines and platysma bands, and is approved for masseter muscle prominence in China. The Juvederm Collection is a range of hyaluronic acid dermal fillers for volume loss in the temples, undereye, cheeks, chin, lips and lower face. Around them sit Alloderm regenerative dermal tissue, CoolSculpting body contouring, Natrelle breast implants, the SkinMedica skincare line, Latisse eyelash solution and DiamondGlow dermabrasion.

Eye care covers Ozurdex, a corticosteroid implant injected into the back of the eye that dissolves naturally, for diabetic macular oedema and non-infectious uveitis; Lumigan, Ganfort, Alphagan and Combigan for lowering intraocular pressure in open-angle glaucoma and ocular hypertension; and Refresh, Optive, Xen, Durysta and Restasis. The other key products are Mavyret, sold as Maviret outside the United States, for chronic hepatitis C; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency, which AbbVie has the rights to sell only in the United States; and Linzess, sold as Constella outside the United States, for irritable bowel syndrome with constipation and chronic idiopathic constipation.

How it reaches the patient

Marketing is aimed first at securing the prescription or recommendation from physicians, external experts and other healthcare providers, with managed care providers, hospitals and state and federal government agencies also important customers. The company markets directly to consumers as well, and runs patient support programmes. Products are generally sold worldwide directly to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies and independent retailers, from AbbVie-owned distribution centres and public warehouses, with aesthetic products and devices also sold directly to physicians and other licensed providers. In 2025 three wholesale distributors, McKesson, Cardinal Health and Cencora, accounted for substantially all of AbbVie's pharmaceutical product sales in the United States, and no individual wholesaler accounted for more than 43% of gross revenues there.

From AbbVie's annual report on Form 10-K for the year ended 31 December 2025. The filing

Compare with another name What $10,000 in AbbVie became

Latest results

Latest quarterQ3 FY2026ended 30 September 2026 · 10-Q filed 3 November 2026
Revenue
$17.4 billion
+10.3% on the year · +2.4% on the quarter
Q4 FY2024Q3 FY2026
Net income
$4.2 billion
+2,167.7% on the year · +16.7% on the quarter
Q4 FY2024Q3 FY2026
Diluted EPS
$2.37
+2,270.0% on the year · +16.7% on the quarter
Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

Read the Q3 FY2026 results →the 10-Q on EDGAR ↗
Last full yearFY2025ended 31 December 2025 · 10-K filed 20 February 2026
Revenue
$61.2 billion
+8.6% on the year
FY2018FY2025
Net income
$4.2 billion
-1.2% on the year
FY2018FY2025
Diluted EPS
$2.36
-1.3% on the year
FY2018FY2025

this yearthe year beforeHover a bar for its figure.

The years before, in wordsAbbVie (ABBV) reported revenue of $61.2 billion for fiscal 2025, the year ended 31 December 2025, up 8.6% on the year before. Net income was $4.2 billion and diluted earnings per share $2.36. Revenue was $56.3 billion in fiscal 2024, $54.3 billion in fiscal 2023, $58.1 billion in fiscal 2022 and $56.2 billion in fiscal 2021. Net income in the same years was $4.3 billion, $4.9 billion, $11.8 billion and $11.5 billion. Over the twelve months to 30 September 2026, AbbVie reported revenue of $66.0 billion and net income of $10.3 billion. Revenue grew 6.0% a year, compounded, over the five years to fiscal 2025. AbbVie declared $6.92 a share in dividends over the last four quarters and had 1.77 billion shares outstanding at the latest filed count. At 30 September 2026 it carried $80.9 billion of debt and $10.8 billion of cash. At the close of 6 November 2026 the market cap of AbbVie was $514.8 billion, 50.1 times its earnings over the last twelve months.
Read the FY2025 results →the 10-K on EDGAR ↗

Ratios

From the filings

ROEn/a
ROCEn/a
Operating margin32.2%
Net margin15.7%
FCF margin28.6%
Interest cover7.1x
Debt to equityn/a
Cash conversion1.94x
Share count, last 12 months0.0%
Sales CAGR, 3 years1.8%
Profit CAGR, 3 years-29.1%
EPS, TTM$5.81

At the close of 6 November 2026

Price$291.24
Market cap$514.8 billion
Stock P/E50.1x
Price to bookn/a
EV / EBITDA20.3x
Dividend yield2.4%
Market cap / sales7.8x
52-week high$294.91
52-week low$197.38
Price, 1 year33.0%
Price CAGR, 3 years27.0%
Price CAGR, 5 years20.0%

29 ready-made ratios, from FCF yield to net debt to EBITDA, wait on the Formulas page, each with what it tells you. Browse and add them →

Worked from the filed figures; hover a name for the formula.
Read moreThe priced ones use the latest price, the last regular-hours trade on IEX. Debt to equity here stands on the borrowing lines of AbbVie Inc.'s balance sheet, added together, finance leases inside them only where the company puts them there; operating leases are a separate line. Nothing here is a valuation or a view.
ABBVgreeksoup.ai
Daily prices to 6 November 2026, adjusted for splits; from 28 September 2026 each day's price is the last regular-hours trade on IEX.
Read moreData provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. Day by day for the last three years; before that one point a week, carrying the week's last close and its average daily volume, so a volume bar means the same thing across the whole series; the bars sit under the price on their own scale, on the right. The moving averages need consecutive days and are drawn from the daily part. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Before the quarters on file begin, P/E, price to book and market cap to sales stand on each annual report from the day it was filed. Drawn in your browser; the range and overlay you pick are remembered here only.

Quarterly results

Q4 FY2021Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022Q1 FY2023Q2 FY2023Q3 FY2023Q4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue14,88613,53814,58314,81215,12112,22513,86513,92714,30112,31014,46214,46015,10213,34315,42315,77616,61815,00216,99017,404
Cost of revenue4,3204,0524,1705,0224,1703,9864,2406,4855,7044,0944,2024,2124,3964,0024,3465,3044,5524,2184,2914,285
Gross profit10,5669,48610,4139,79010,9518,2399,6257,4428,5978,21610,26010,24810,7069,34111,07710,47212,06610,78412,69913,119
Gross margin71%70%71%66%72%67%69%53%60%67%71%71%71%70%72%66%73%72%75%75%
R&D1,8271,4971,6091,6141,7902,2921,7331,7231,9271,9391,9482,1306,7742,0672,1312,3192,5792,4722,3442,567
SG&A3,2603,1275,4123,3043,4173,0393,2683,3723,1933,3153,3774,2053,8553,2933,2533,5693,8953,5783,6324,087
Operating income5,0744,7173,2954,6035,5022,7684,5132,2813,1952,7983,9983,831-1,4903,7334,8941,9044,5443,9906,4326,267
Operating margin34%35%23%31%36%23%33%16%22%23%28%26%-10%28%32%12%27%27%38%36%
Interest expense580548556560566553552555564660726720702700740739714717746802
Pre-tax income4,2714,9291,1834,4002,9654752,6101,9531,2121,7552,1462,084-2,2691,6611,5547142,6681,0394,2784,829
Tax rate5%9%22%10%17%49%22%9%32%22%36%25%n/a22%39%74%32%33%15%13%
Net income4,0444,4909243,9492,4732392,0241,7788221,3691,3701,561-22.01,2869381861,8166953,6134,218
Net margin27%33%6%27%16%2%15%13%6%11%9%11%-0%10%6%1%11%5%21%24%
Diluted EPS$2.26$2.51$0.51$2.21$1.38$0.13$1.14$1.00$0.46$0.77$0.77$0.88-$0.02$0.72$0.52$0.10$1.02$0.39$2.03$2.37
Operating cash flow5,0754,9085,0057,6027,4284,1936,3197,5744,7534,0402,2715,4477,0481,6355,1537,0245,2183,8293,4367,606
Capital expenditure187162143177213175178219205193241249291235269381329265322301
Free cash flow4,8884,7464,8627,4257,2154,0186,1417,3554,5483,8472,0305,1986,7571,4004,8846,6434,8893,5643,1147,305
Buybacks1311,4709.04.04.01,95510.04.03.01,3249.017.035896112.04.03.01,4899.05.0
Dividends paid2,3142,5262,5072,5042,5062,6612,6252,6272,6262,7722,7502,7512,7522,9252,9102,9112,9113,0863,0703,071
Shares outstanding1,769m1,767m1,768m1,768m1,769m1,764m1,765m1,766m1,766m1,766m1,766m1,767m1,765m1,766m1,767m1,767m1,768m1,767m1,767m1,768m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read moreMoney is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Income statement (profit and loss)

FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Revenue17,44418,38018,79019,96022,85925,63828,21632,75333,26645,80456,19758,05454,31856,33461,16066,014
Cost of revenue4,6394,5084,5814,4264,5005,8327,0427,7187,43915,38717,44617,41420,41516,90418,20417,346
Gross profit12,80513,87214,20915,53418,35919,80621,17425,03525,82730,41738,75140,64033,90339,43042,95648,668
Gross margin73.4%75.5%75.6%77.8%80.3%77.3%75.0%76.4%77.6%66.4%69.0%70.0%62.4%70.0%70.2%73.7%
Research and development2,6182,7782,8553,2974,2854,3855,00710,3296,4076,3796,9226,5107,67512,7919,0969,962
Selling, general and administrative5,8944,9895,3527,7246,3875,8816,2957,3996,94211,29912,34915,26012,87214,75214,01015,192
Operating income3,6205,8175,6643,4117,5379,3409,5456,38312,98311,36317,92418,11712,7579,13715,07521,233
Operating margin20.8%31.6%30.1%17.1%33.0%36.4%33.8%19.5%39.0%24.8%31.9%31.2%23.5%16.2%24.6%32.2%
Interest expensen/a1042994297191,0471,1501,3481,7842,4542,4232,2302,2242,8082,8932,979
Pre-tax income3,6685,7255,3322,3696,6457,8847,7275,1978,4263,39812,98913,4776,2503,7166,59712,814
Income tax2354501,2045951,5011,9312,418-490544-1,2241,4401,6321,377-5702,3642,466
Effective tax rate6.4%7.9%22.6%25.1%22.6%24.5%31.3%-9.4%6.5%-36.0%11.1%12.1%22.0%-15.3%35.8%19.2%
Net income3,4335,2754,1281,7745,1445,9535,3095,6877,8824,61611,54211,8364,8634,2784,22610,342
Net margin19.7%28.7%22.0%8.9%22.5%23.2%18.8%17.4%23.7%10.1%20.5%20.4%9.0%7.6%6.9%15.7%
Diluted EPS$2.18$3.35$2.56$1.10$3.13$3.63$3.30$3.66$5.28$2.72$6.45$6.63$2.72$2.39$2.36$5.81
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
From each year's 10-K, linked; TTM is the last four quarters.
Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Revenue by region FY2011 to FY2025

FY2011FY2012FY2013FY2014FY2015FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025Share
of the parts, latest year
United States9,71210,43510,18110,84513,56115,94718,25121,52423,90734,87943,51045,71341,88343,02946,60376.2%
All other countries2,6742,7763,6713,8964,0013,8854,0803,8633,5663,9774,7614,8375,0425,4495,7599.4%
Germany7017569111,0351,0821,1041,1571,2929091,0491,2231,3401,2661,4651,7382.8%
Japan6167186255815997707641,5911,2111,1981,0909561,0081,1221,2742.1%
Canada4465005385515516246597308131,1591,3971,1591,0761,0881,2222.0%
Chinan/an/an/an/an/an/an/a1521954718579129509171,0061.6%
France5165005405845977137307836957979367877807768061.3%
United Kingdom4965526067226887768078553725094974624175226261.0%
Spain5695255435346185895216114724535195065015286091.0%
Italy4284084044324525234756523723795064444845115800.9%
Brazil3824344394353763554103503594063684304394644780.8%
Australian/an/an/an/an/an/an/a3503955275335084724634590.8%
Netherlands904776332345334352362n/an/an/an/an/an/an/an/an/a
United StatesAll other countriesGermanyJapanCanadaChina FY2018 to FY2025FranceNetherlands FY2011 to FY2017Other
17.4FY201118.8FY201322.9FY201528.2FY201733.3FY201956.2FY202154.3FY202361.2FY2025

$ billion; hover a block for its figure and share; a part named with years is one the company split its revenue into only then

From the company's 10-Ks, in its own words (latest 10-K).
Read moreEach year's figures come from the most recent 10-K that includes that year. A year is shown only where the parts add up to the revenue above. Fiscal years are labelled by the year they end in.

First forecast against the result

AbbVie's adjusted EPS landed at or above the top of the range in 6 and under it in 3 of the 9 years shown (FY2017 to FY2025).

+1.1%FY2017+6.5%FY2018+2.2%FY2019+8.8%FY2020+1.4%FY2021−3.0%FY2022+0.1%FY2023−10.0%FY2024−18.8%FY2025
  • At or above the top of the range
  • Inside the range
  • Under the range

Each bar is the year's result against the top of its first forecast range, in per cent of the top. Hover a bar for the figures.

Fiscal yearFirst forecast
adjusted EPS		Result
FY2017$5.44 to $5.54$5.60
FY2018$7.33 to $7.43$7.91
FY2019$8.65 to $8.75$8.94
FY2020$9.61 to $9.71$10.56
FY2021$12.32 to $12.52$12.70
FY2022$14.00 to $14.20$13.77 incl. $0.39 IPR&D
FY2023$10.70 to $11.10$11.11 incl. $0.42 IPR&D
FY2024$11.05 to $11.25$10.12 incl. $1.52 IPR&D
FY2025$12.12 to $12.32$10.00 incl. $2.76 IPR&D
FY2026 forecast
Adjusted EPS $14.37 to $14.57, given 4 February 2026. Its result comes with the fourth-quarter results for FY2026.
Acquired research
The result includes the cost of research bought from other companies (acquired IPR&D and milestones), per share as the company states it in the same release: FY2022 $0.39, FY2023 $0.42, FY2024 $1.52 and FY2025 $2.76.
First forecast
The full-year range the company gave with its fourth-quarter results for the year before, before any later change to it.
Result
The figure the company reported for that year with its next fourth-quarter results.
Adjusted EPS
The company's own measure, which leaves out items it names, so it differs from the EPS in the tables above.
Years left out
Where the forecast or the result could not be read with confidence. Each figure in the table links to the results release it comes from.

Cash flow

FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Operating cash flow6,2476,3456,2673,5497,5357,0419,96013,42713,32417,58822,77724,94322,83918,80619,03020,089
Capital expenditure3563334916125324795296385527987876957779741,2141,217
Free cash flow5,8916,0125,7762,9377,0036,5629,43112,78912,77216,79021,99024,24822,06217,83217,81618,872
Free cash flow margin33.8%32.7%30.7%14.7%30.6%25.6%33.4%39.0%38.4%36.7%39.1%41.8%40.6%31.7%29.1%28.6%
Cash from investingn/an/an/an/an/an/a-274-1,006596-37,557-2,344-623-2,009-20,820-6,643-13,449
Cash from financingn/an/an/an/an/a-3,928-5,512-14,39618,708-11,501-19,039-24,803-17,222-5,211-12,724-1,481
Depreciation and amortisation1,2721,1508977868361,1891,5011,7652,0176,4718,5218,4678,6988,3868,1397,644
Share-based compensation163187212241282353365421430753692671747911955927
Buybacksn/an/a3206657,5866,0331,41012,0146299789341,4871,9721,7089801,506
Dividends paidn/an/a2,5552,6613,2943,7174,1075,5806,3667,7169,26110,04310,53911,02511,65712,138
Dividend per sharen/an/a$2.00$1.75$2.10$2.35$2.63$3.95$4.39$4.84$5.31$5.71$5.99$6.29$6.65$6.92
Diluted shares, weighted1,577m1,577m1,604m1,610m1,637m1,631m1,603m1,546m1,484m1,673m1,777m1,778m1,773m1,773m1,773m1,772m
Shares outstanding at period endn/an/an/an/an/an/an/an/an/an/an/an/an/an/an/a1,768m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
Cash paid in the year, from the cash flow statement.
Read moreThe dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet

FY2011FY2012FY2013FY2014 †FY2015 †FY2016 †FY2017 †FY2018FY2019FY2020 †FY2021 †FY2022FY2023FY2024FY2025TTM
Funded by
Shareholders' equityn/a-3504,4921,7423,9454,6365,097-8,446-8,17213,07615,40817,25410,3603,325-3,270-4,583
Non-controlling interestn/an/an/an/an/an/an/an/a0.021.028.033.037.039.042.045.0
Short-term borrowingsn/an/an/an/an/an/an/an/a0.0n/an/a1.00.00.0n/an/a
Debtn/a15,67214,72314,97731,67136,84237,36840,31067,23386,05676,68463,12859,24566,84167,49680,903
Operating lease liabilitiesn/an/an/an/an/an/an/an/an/a832713754735697689n/a
Finance lease liabilitiesn/an/an/an/an/an/an/an/an/a21.025.017.027.023.022.0n/a
Other liabilitiesn/a11,6869,98310,82817,43424,62128,32127,48830,05450,55953,67157,61864,30764,23668,98171,315
Total liabilities and equityn/a27,00829,19827,54753,05066,09970,78659,35289,115150,565146,529138,805134,711135,161133,960147,680
Owned
Fixed assetsn/a2,2472,2982,4852,5652,6042,8032,8832,9625,2485,1104,9354,9895,1345,6285,941
Goodwill6,1006,1306,2775,86213,16815,41615,78515,66315,60433,12432,37932,15632,29334,95635,64037,800
Intangible assetsn/a2,3231,8901,51319,70928,89727,55921,23318,64982,87675,95167,43955,61060,06852,64156,652
Investmentsn/a2,1944181181533,1062,5762,19293.0323361269306310296387
Cash and equivalents27.05,9019,5958,3488,3995,1009,3037,28939,9248,4499,7469,20112,8145,5245,22910,774
Receivablesn/an/an/an/a4,7304,7585,0885,3845,4288,8229,97711,25411,15510,91912,58913,509
Inventoryn/a1,0911,1501,1241,7191,4441,6051,6051,8133,3103,1283,5794,0994,1814,9515,305
Other assetsn/a7,1227,5708,0972,6074,7746,0673,1034,6428,4139,8779,97213,44514,06916,98617,312
Total assetsn/a27,00829,19827,54753,05066,09970,78659,35289,115150,565146,529138,805134,711135,161133,960147,680
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K
At the fiscal year end; the TTM column is the latest quarter end.
Read moreBoth totals are the company's own. Other liabilities is the filed total less the rows above it: payables, deferred revenue, taxes, borrowings the rows above do not carry and the rest; other assets is the same on the other side. Investments add the current and non-current lines as filed. Debt is the company's own stated total where it files one, otherwise its long-term debt with the current maturities, never parts added together. A row is left blank in a year where the lines shown overlap and the remainder would fall below nil.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded10.3%6.0%1.8%10.7%
Profit growth, compounded-1.9%-1.7%-29.1%333.1%
Return on equity, averagen/a79.8%87.8%n/a
Yearly growth, compounded; TTM is the last four quarters against the four before.
Read moreReturn on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Questions

What was AbbVie's revenue in fiscal 2025?

AbbVie (ABBV) reported revenue of $61.2 billion for fiscal 2025, the year ended 31 December 2025, up 8.6% on the year before.

How much did AbbVie earn in fiscal 2025?

Net income was $4.2 billion for fiscal 2025, and diluted earnings per share $2.36.

What is AbbVie's P/E ratio?

At the close of 6 November 2026, AbbVie traded at 50.1 times its earnings over the twelve months to 30 September 2026.

What is AbbVie's market cap?

The market cap of AbbVie was $514.8 billion at the close of 6 November 2026.

Does AbbVie pay a dividend?

Yes. AbbVie declared $6.92 a share in dividends over the four quarters to 30 September 2026.

Peers: Pharmaceutical Products

CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
All 175 in Pharmaceutical Products
CompanyMarket capP/EROEOp. marginSales growth
TTM		Debt to equityDiv. yield
Eli Lilly & Co. LLY$1.27 trillion43.9868.5%n/a45.5%1.230.5%
Johnson & Johnson JNJ$665.0 billion41.8619.7%n/a7.8%0.551.9%
AbbVie Inc. ABBV$514.8 billion50.13n/a32.2%10.7%n/a2.4%
Merck & Co., Inc. MRK$361.8 billion151.295.5%n/a4.9%1.202.3%
Novartis AG NVS *$310.3 billion22.7530.3%n/a8.4%0.622.5%
AstraZeneca PLC AZN *$289.1 billion28.5121.0%23.4%8.6%0.571.7%
Amgen Inc. AMGN$249.0 billion26.7065.4%32.4%8.2%3.762.2%
Gilead Sciences, Inc. GILD$207.1 billionn/a-29.6%-7.6%6.5%2.011.9%
Abbott Laboratories ABT$190.5 billion41.039.2%13.8%10.0%0.612.3%
Novo Nordisk A/S NVO *$179.9 billion11.7152.8%41.3%6.4%0.674.4%
Pfizer Inc. PFE$167.5 billion41.984.5%n/a1.3%0.705.9%
Vertex Pharmaceuticals Inc. VRTX$138.7 billion35.1919.0%33.2%10.5%0.22n/a
Bristol-Myers Squibb Co. BMY$127.0 billion13.7839.5%22.6%4.2%1.834.1%
Sanofi SNY *$114.7 billion13.2210.9%n/a6.2%0.264.7%
Moderna, Inc. MRNA$102.7 billionn/a-40.8%-116.0%13.1%0.52n/a
GSK plc GSK *$101.0 billion13.5334.9%24.3%4.1%1.083.4%
Regeneron Pharmaceuticals, Inc. REGN$95.5 billion19.9714.4%28.8%18.6%0.060.4%
Takeda Pharmaceutical Company Limited TAK *$66.4 billionn/a-2.1%0.1%-1.7%0.663.1%
argenx SE ARGX *$57.4 billion47.4317.6%n/a89.9%0.00n/a
IDEXX Laboratories Inc. IDXX$53.3 billion45.5863.2%32.3%11.9%0.45n/a
Teva Pharmaceutical Industries Ltd. TEVA$49.7 billion99.096.4%8.3%2.7%2.10n/a
Royalty Pharma plc RPRX$37.5 billion44.276.9%57.1%11.4%0.881.4%
Biogen Inc. BIIB$36.7 billion106.201.8%4.3%2.3%0.41n/a
Genmab A/S GMAB *$34.5 billion34.8916.5%28.6%19.2%0.90n/a
Zoetis Inc. ZTS$32.4 billion13.5175.3%n/a1.0%2.742.6%
Roivant Sciences Ltd. ROIV$28.1 billionn/a-6.3%-7,914.8%-67.6%0.00n/a
Insmed Inc. INSM$25.1 billionn/a-83.4%-37.1%240.0%0.76n/a
United Therapeutics Corp. UTHR$23.8 billion21.2119.6%41.4%1.9%0.00n/a
Viatris Inc. VTRS$22.8 billionn/a-4.4%-0.0%4.3%0.972.4%
BioNTech SE BNTX *$22.0 billionn/a-5.9%-49.0%4.3%0.01n/a
Alnylam Pharmaceuticals, Inc. ALNY$20.9 billion8.1075.6%19.5%56.2%0.28n/a
Exelixis, Inc. EXEL$17.0 billion20.8348.3%40.2%9.1%0.00n/a
Neurocrine Biosciences Inc. NBIX$16.7 billion24.4318.1%24.0%38.0%0.00n/a
Jazz Pharmaceuticals plc JAZZ$15.1 billion79.824.9%9.0%13.5%1.33n/a
Kiniksa Pharmaceuticals International, plc KNSA$14.7 billion72.1615.4%13.8%58.2%0.00n/a
BridgeBio Pharma, Inc. BBIO$14.6 billionn/an/a-38.5%167.3%n/an/a
Elanco Animal Health Inc. ELAN$12.9 billionn/a-2.2%n/a12.1%0.52n/a
Dr. Reddy’s Laboratories Limited RDY *$12.4 billion27.5111.4%15.0%3.2%0.210.6%
Halozyme Therapeutics, Inc. HALO$11.8 billion26.38n/a37.4%45.0%n/an/a
Bio-Techne Corp. TECH$11.4 billion66.787.9%19.6%0.9%0.090.4%
Kymera Therapeutics, Inc. KYMR$11.2 billionn/a-21.6%-396.0%133.8%0.00n/a
Biomarin Pharmaceutical Inc. BMRN$10.8 billionn/a-0.3%3.1%18.1%0.67n/a
Repligen Corp. RGEN$9.8 billionn/a-0.6%2.3%13.8%0.27n/a
Madrigal Pharmaceuticals, Inc. MDGL$9.3 billionn/a-24.8%-10.7%92.8%0.54n/a
TG Therapeutics, Inc. TGTX$9.2 billion21.8273.1%17.1%76.1%1.23n/a
ImmunityBio, Inc. IBRX$9.1 billionn/an/a-151.9%192.9%n/an/a
Krystal Biotech, Inc. KRYS$8.9 billion40.8215.7%48.4%26.0%0.00n/a
Protagonist Therapeutics, Inc. PTGX$8.6 billion27.9731.5%58.6%163.7%0.00n/a
Arrowhead Pharmaceuticals, Inc. ARWR$8.2 billionn/a-68.7%-33.8%16.8%1.86n/a
Corcept Therapeutics Inc. CORT$8.0 billion57.2419.5%11.5%30.0%0.00n/a
Rhythm Pharmaceuticals, Inc. RYTM$7.8 billionn/a-220.3%-66.7%61.0%1.17n/a
Alkermes plc. ALKS$7.7 billionn/a-0.0%3.7%15.3%0.81n/a
Twist Bioscience Corp. TWST$7.6 billionn/a-30.7%-33.6%19.2%0.03n/a
Cytokinetics Inc. CYTK$7.5 billionn/an/a-625.2%29.9%n/an/a
Axsome Therapeutics, Inc. AXSM$7.0 billionn/a-149.2%-17.5%54.2%1.78n/a
CG Oncology, Inc. CGON$6.8 billionn/a-24.0%-4,293.5%183.6%0.00n/a
Lantheus Holdings, Inc. LNTH$6.6 billion24.7819.9%18.6%2.4%0.42n/a
Ionis Pharmaceuticals Inc. IONS$6.5 billionn/a-128.5%-68.0%-7.4%3.01n/a
Amneal Pharmaceuticals, Inc. AMRX$6.4 billion41.10476.5%14.6%9.3%80.86n/a
Ligand Pharmaceuticals Inc. LGND$6.1 billion136.655.4%9.5%1.0%1.17n/a
Mirum Pharmaceuticals, Inc. MIRM$6.1 billionn/an/a-133.6%42.2%n/an/a
Scholar Rock Holding Corp. SRRK$5.7 billionn/an/an/an/a0.77n/a
PTC Therapeutics, Inc. PTCT$5.5 billionn/an/a12.8%-35.1%n/an/a
Crispr Therapeutics AG CRSP$4.9 billionn/a-27.7%-2,114.8%-34.3%0.36n/a
Gossamer Bio, Inc. GOSS$4.8 billionn/an/a-311.7%32.4%n/an/a
Travere Therapeutics, Inc. TVTX$4.7 billionn/a-538.0%-20.5%49.4%26.72n/a
Adaptive Biotechnologies Corp. ADPT$4.5 billionn/a-40.0%-16.2%17.9%1.90n/a
Relay Therapeutics, Inc. RLAY$4.1 billionn/a-35.9%-3,094.9%23.9%0.00n/a
Liquidia Corp. LQDA$4.0 billion32.3971.0%37.4%2,233.6%n/an/a
Xenon Pharmaceuticals Inc. XENE$3.8 billionn/a-32.9%n/an/a0.00n/a
Iovance Biotherapeutics, Inc. IOVA$3.7 billionn/a-27.1%-60.8%51.3%0.00n/a
Acadia Pharmaceuticals Inc. ACAD$3.7 billion10.0626.1%10.2%14.8%0.00n/a
AbCellera Biologics Inc. ABCL$3.6 billionn/a-18.4%-340.2%101.3%0.00n/a
Organon & Co. OGN$3.6 billion18.2217.9%n/a-3.2%7.170.6%
Tango Therapeutics, Inc. TNGX$3.6 billionn/a-12.1%-253.4%121.5%0.00n/a
Viking Therapeutics, Inc. VKTX$3.4 billionn/a-106.6%n/an/a0.43n/a
Tarsus Pharmaceuticals, Inc. TARS$3.4 billionn/a-675.0%-102.0%86.3%0.700.0%
Supernus, Inc. INDV$3.3 billion7.88n/a40.6%16.4%n/an/a
DBV Technologies S.A. DBVT$3.3 billionn/a-139.5%-5,420.1%-31.5%0.00n/a
Viridian Therapeutics, Inc. VRDN$3.2 billionn/a-78.1%-1,781.4%-62.8%0.63n/a
Arcutis Biotherapeutics, Inc. ARQT$3.2 billion121.6412.3%6.9%60.0%0.45n/a
Denali Therapeutics Inc. DNLI$3.2 billionn/an/an/an/a0.00n/a
Supernus, Inc. SUPN$3.1 billion9.62n/a45.5%16.2%n/an/a
Bausch Health Companies Inc. BHC$3.1 billionn/an/a11.2%10.8%n/an/a
Ideaya Biosciences, Inc. IDYA$3.0 billionn/an/an/an/a0.00n/a
Adma Biologics, Inc. ADMA$2.8 billion16.5241.6%46.5%6.3%0.45n/a
Silence Therapeutics plc SLN$2.8 billionn/a-155.8%-11,106.8%-97.7%0.00n/a
Vericel Corp. VCEL$2.8 billion85.298.7%8.3%25.3%0.00n/a
Xeris Biopharma Holdings, Inc. XERS$2.8 billionn/a-13.3%12.7%38.4%3.89n/a
Beam Therapeutics Inc. BEAM$2.7 billionn/a-11.2%-267.7%163.3%0.11n/a
Xencor Inc. XNCR$2.7 billionn/a-21.0%-72.7%33.5%0.17n/a
Neogen Corp. NEOG$2.6 billionn/a-2.7%-0.8%-0.3%0.37n/a
Celldex Therapeutics, Inc. CLDX$2.3 billionn/a-47.6%-213,033.8%-94.0%0.00n/a
Arcus Biosciences, Inc. RCUS$2.3 billionn/a-126.5%-475.0%-58.3%0.28n/a
NewAmsterdam Pharma Co. N.V. NAMS$2.3 billionn/a-32.5%-900.1%-26.4%0.00n/a
Schrodinger, Inc. SDGR$2.2 billionn/a-19.6%-49.6%4.8%0.00n/a
Septerna, Inc. SEPN$2.2 billionn/a-6.3%-44.0%13,520.1%0.00n/a
Aurinia Pharmaceuticals Inc. AUPH$2.2 billion7.1947.8%48.6%21.0%0.00n/a
Perrigo Co. plc PRGO$2.2 billionn/a-72.5%-39.4%-4.5%1.357.3%
Immunome Inc. IMNM$2.1 billionn/a-48.4%n/an/a0.00n/a
Zymeworks Inc. ZYME$2.1 billionn/a-186.6%-419.0%-69.8%0.00n/a
Vir Biotechnology, Inc. VIR$2.1 billionn/a-20.6%-69.8%1,696.0%0.00n/a
Prestige Consumer Healthcare Inc. PBH$2.0 billion13.268.0%25.0%5.1%1.07n/a
Recursion Pharmaceuticals, Inc. RXRX$2.0 billionn/a-52.5%-725.4%56.2%0.01n/a
Trulieve Cannabis Corp. TRLV$2.0 billionn/a-57.8%-25.6%-9.1%0.37n/a
Biocryst Pharmaceuticals Inc. BCRX$2.0 billionn/an/a-30.1%60.3%n/an/a
Harmony Biosciences Holdings, Inc. HRMY$1.9 billion10.9616.7%22.2%19.8%0.14n/a
Zenas BioPharma, Inc. ZBIO$1.9 billionn/an/an/an/a1.41n/a
Sarepta Therapeutics, Inc. SRPT$1.9 billionn/a-7.5%-2.5%-18.9%0.56n/a
Maze Therapeutics, Inc. MAZE$1.9 billionn/an/an/an/a0.09n/a
Novavax Inc. NVAX$1.8 billionn/an/a-21.2%-61.3%n/an/a
Agios Pharmaceuticals, Inc. AGIO$1.8 billionn/a-38.1%-297.7%214.4%0.00n/a
Stoke Therapeutics, Inc. STOK$1.7 billionn/a-69.0%-913.1%-86.3%0.00n/a
Generate Biomedicines, Inc. GENB$1.7 billionn/an/an/an/a0.00n/a
Nurix Therapeutics, Inc. NRIX$1.7 billion6.6130.5%41.3%738.8%0.000.0%
Eton Pharmaceuticals, Inc. ETON$1.6 billion37.1357.4%28.8%100.6%0.27n/a
Immunocore Holdings plc IMCR$1.6 billionn/a-7.7%-6.8%13.1%0.940.0%
Precigen, Inc. PGEN$1.6 billion128.0629.1%21.4%n/a1.12n/a
Intellia Therapeutics, Inc. NTLA$1.6 billionn/a-69.5%-821.2%-8.1%0.12n/a
Ultragenyx Pharmaceutical Inc. RARE$1.6 billionn/an/a-64.0%15.8%n/an/a
uniQure N.V. QURE$1.5 billionn/a-79.0%-1,001.7%28.0%0.17n/a
ANI Pharmaceuticals Inc. ANIP$1.5 billion13.2818.3%16.0%25.9%0.95n/a
Pacira BioSciences, Inc. PCRX$1.5 billion39.175.3%4.8%3.7%0.41n/a
Ocular Therapeutix, Inc. OCUL$1.4 billionn/a-58.0%-603.0%-8.1%0.14n/a
Nuvation Bio Inc. NUVB$1.4 billionn/a-59.6%-61.2%654.2%1.25n/a
Korsana Biosciences, Inc. KRSA$1.4 billionn/an/an/an/a0.00n/a
Taysha Gene Therapies, Inc. TSHA$1.4 billionn/a-38.6%-2,792.3%-32.3%0.13n/a
Innoviva, Inc. INVA$1.4 billion9.6017.0%38.8%12.8%0.23n/a
Phibro Animal Health Corp. PAHC$1.3 billion13.1824.6%12.5%10.1%1.761.5%
Cronos Group Inc. CRON$1.3 billion21.295.4%3.4%55.8%0.00n/a
Avalyn Pharma Inc. AVLN$1.3 billionn/an/an/an/a0.04n/a
Opko Health, Inc. OPK$1.3 billionn/a-13.3%-25.5%-21.9%0.43n/a
Mannkind Corp. MNKD$1.3 billionn/an/a-2.9%31.7%n/an/a
Inhibrx Biosciences, Inc. INBX$1.2 billionn/an/an/an/an/an/a
Omeros Corp. OMER$1.2 billionn/an/an/an/an/an/a
Amphastar Pharmaceuticals, Inc. AMPH$1.2 billion13.0112.1%18.7%3.1%0.75n/a
UroGen Pharma Ltd. URGN$1.2 billionn/an/a-12.4%159.3%n/an/a
Rapport Therapeutics, Inc. RAPP$1.2 billionn/an/an/an/a0.00n/a
Janux Therapeutics, Inc. JANX$1.1 billionn/a-11.0%-599.3%132.9%0.00n/a
Harrow, Inc. HROW$1.0 billionn/a-244.9%-1.0%21.1%19.24n/a
Cryoport, Inc. CYRX$969 millionn/a-7.8%-20.0%1.1%0.39n/a
Odyssey Therapeutics, Inc. ODTX$921 millionn/an/an/an/a0.00n/a
Monte Rosa Therapeutics, Inc. GLUE$901 millionn/a-26.4%-214.5%-61.3%0.00n/a
Syndax Pharmaceuticals Inc. SNDX$857 millionn/an/a-61.7%159.5%n/an/a
MeiraGTx Holdings plc MGTX$847 million12.6636.6%46.3%948.3%0.46n/a
Aktis Oncology, Inc. AKTS$847 millionn/an/an/an/a0.00n/a
Verastem, Inc. VSTM$794 millionn/an/an/an/a11.82n/a
Lexicon Pharmaceuticals, Inc. LXRX$791 millionn/a-38.1%-147.4%-45.6%0.32n/a
Nektar Therapeutics NKTR$759 millionn/a-17.4%-257.8%-27.2%0.00n/a
Collegium Pharmaceutical, Inc. COLL$752 million24.2012.9%15.2%7.7%3.65n/a
Rigel Pharmaceuticals Inc. RIGL$746 million2.5569.0%26.3%2.2%0.02n/a
QuidelOrtho Corp. QDEL$732 millionn/a-20.6%-4.9%-4.5%1.64n/a
Ironwood Pharmaceuticals Inc. IRWD$728 million4.89n/a62.9%18.1%n/an/a
Ardelyx, Inc. ARDX$722 millionn/a-33.8%-7.7%17.6%1.54n/a
Arbutus Biopharma Corp. ABUS$721 million4.6259.2%82.0%1,078.8%0.00n/a
Ginkgo Bioworks Holdings, Inc. DNA$718 millionn/a-69.2%-259.9%-51.5%0.00n/a
Zevra Therapeutics, Inc. ZVRA$690 million9.6032.7%60.8%75.1%0.00n/a
Wave Life Sciences, Inc. WVE$665 millionn/a-52.4%-320.9%n/a0.00n/a
Design Therapeutics, Inc. DSGN$651 millionn/a-36.6%n/an/a0.00n/a
Kura Oncology, Inc. KURA$645 millionn/a-612.8%-411.9%n/a0.20n/a
Geron Corp. GERN$636 millionn/an/an/an/a0.53n/a
Aclaris Therapeutics, Inc. ACRS$588 millionn/a-47.7%-1,414.0%-59.3%0.00n/a
Myriad Genetics Inc. MYGN$565 millionn/a-48.0%-14.3%-2.6%0.45n/a
Gyre Therapeutics, Inc. GYRE$510 millionn/a-37.5%-20.6%13.5%0.00n/a
Monopar Therapeutics MNPR$479 millionn/an/an/an/a0.00n/a
CytomX Therapeutics, Inc. CTMX$476 millionn/a-30.0%-676.5%-87.7%0.00n/a
Aquestive Therapeutics, Inc. AQST$454 millionn/an/a-114.1%12.5%n/an/a
Evolus, Inc. EOLS$450 millionn/an/a-4.8%13.9%n/an/a
Phathom Pharmaceuticals, Inc. PHAT$425 millionn/an/a-9.3%86.8%n/an/a
Puma Biotechnology, Inc. PBYI$421 million15.8519.3%13.2%-2.9%0.00n/a
Arvinas, Inc. ARVN$419 millionn/a-1.8%-12.1%-11.8%0.00n/a
CorMedix Inc. CRMD$412 million2.4840.6%47.0%n/a0.00n/a
Crescent Biopharma, Inc. CBIO$374 millionn/an/an/an/a0.00n/a
Canopy Growth Corp. CGC$276 millionn/an/a-54.2%10.7%0.38n/a
Atrium Therapeutics, Inc. RNA$143 millionn/an/an/an/an/an/a
125 companies share its SEC industry code (Pharmaceutical Preparations); the rest are the names nearest in size in its wider industry, Pharmaceutical Products, one of the Fama-French 48 industries, a published grouping of SEC industry codes.
Read moreBy market capitalisation; a click on a heading sorts by it, largest first, and a second click turns it round. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close; a name marked * is a foreign company that files once a year, on its latest fiscal year.

The public record on ABBV

Dividends$6.92 a share over the four quarters to 30 September 2026, a 2.38% yield
Filings27 in twelve months: 17 current reports (8-K), about 8 results of operations; 4 other events; 2 officer or director change; 2 regulation FD disclosure; 1 shareholder vote
Planned insider sales5 Form 144 notices in twelve months, $21.7 million; latest 14 August 2026
Options tapeput/call 0.86 by open interest at the 6 November 2026 close; the straddle prices a 3.2% move to 13 November 2026
13F holders4,254 funds reported a position for the quarter to 30 June 2026; largest BlackRock, Inc.
Insider trading6 sales and 0 purchases on Form 4 in twelve months
Congress2 House trades disclosed in six months
Short interest15.6 million shares short, 2.72 days to cover at 15 October 2026
Documentsthe 10-K, the 10-Qs, the proxy and 8 earnings press releases, each linked

Filings

FilingPeriodFiledWhere
10-Q30 September 20263 November 2026EDGAR
10-Q30 June 20263 August 2026EDGAR
10-Q31 March 20268 May 2026EDGAR
10-K31 December 202520 February 2026EDGAR
10-Q30 September 20254 November 2025EDGAR
10-Q30 June 20254 August 2025EDGAR
10-Q31 March 20259 May 2025EDGAR
10-K31 December 202414 February 2025EDGAR
10-Q30 September 20244 November 2024EDGAR
10-Q30 June 20247 August 2024EDGAR

Reading about a stock somewhere else? Our free Chrome extension, GreekSoup Stock Ticker Lookup: Earnings, Insider Trades, 13F Holders, shows the latest quarter against a year ago, insider trades and 13F holders when you hover a $ticker such as $AAPL.